Clinical trial NCT05502237: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Official title: A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Non-small Cell Lung Cancer
Lead sponsor: Gilead Sciences
Sponsor class: INDUSTRY
Collaborators: name: Arcus Biosciences, Inc.
First posted: 2022-08-16
Enrollment: 1069
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.


Eligibility criteria: Key Inclusion Criteria:

* Life expectancy ≥ 3 months.
* Pathologically documented NSCLC that meets both of the criteria below:

  * Have documented evidence of Stage IV NSCLC disease at the time of enrollment (based on American Joint Committee on Cancer (AJCC), Eighth Edition).
  * Have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations.
* Have no actionable genomic alterations such as ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), proto-oncogene B-raf (BRAF), RET mutations, or other driver oncogenes with approved frontline therapies.
* Have not received prior systemic treatment for metastatic NSCLC.
* Measurable disease per RECIST v1.1 criteria by investigator assessment.
* Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
* Have adequate organ functions.

Key Exclusion Criteria:

* Have mixed small-cell lung cancer (SCLC) and NSCLC histology.
* Positive serum pregnancy test or individuals who are breastfeeding or have plans to breastfeed during the study period.
* Received prior treatment with any anti-PD-1, anti-PD-L1, or any other antibody targeting an immune checkpoint.
* Known hypersensitivity to the study drug, its metabolites, or formulation excipient.
* Have an active second malignancy or have had an active second malignancy within 3 years prior to enrollment.
* Have an active autoimmune disease that required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).
* Are receiving chronic systemic steroids.
* Have significant third-space fluid retention.
* Have untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.
* Active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months of enrollment.
* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
* Has had an allogenic tissue/solid organ transplant.
* Have received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.
* Have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Primary outcomes:
measure: Overall Survival (OS) in Participants With Positive Programmed Cell Death-Ligand 1 (PD-L1) Expression (≥1%Tumor Cells) and in all Randomized Participants.
timeFrame: Up to 68 months
Secondary outcomes:
measure: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
timeFrame: Upt to 50 months
measure: Objective Response Rate (ORR) as Assessed by BICR per RECIST Version 1.1
timeFrame: Up to 50 Months
measure: Duration of Response (DOR) as Assessed by BICR per RECIST Version 1.1
timeFrame: Up to 50 Months
measure: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
timeFrame: First dose date up to 50 months plus 30 days
measure: Percentage of Participants Experiencing Clinical Laboratory Abnormalities
timeFrame: First dose date up to 50 months plus 30 days
measure: Time to First Symptom Deterioration in Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) Total Score
timeFrame: Baseline, Up to 50 Months
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Palo Verde Hematology Oncology Ltd
state: Arizona
city: San Marcos
country: United States
facility: California Cancer Associates for Research and Excellence
state: California
city: Santa Barbara
country: United States
facility: Texas Oncology
state: California
city: Whittier
country: United States
facility: Innovative Clinical Research Institute
state: California
city: Norwich
country: United States
facility: Eastern CT Hematology and Oncology Associates
state: Connecticut
city: Lake City
country: United States
facility: Lake City Cancer Care
state: Florida
city: Sarasota
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Tampa
country: United States
facility: Moffitt Cancer Center
state: Florida
city: Atlanta
country: United States
facility: Peachtree Hematology Oncology Consultants
state: Georgia
city: Peoria
country: United States
facility: Illinois Cancer Care
state: Illinois
city: Asheville
country: United States
facility: Messino Cancer Centers
state: North Carolina
city: Cincinnati
country: United States
facility: Oncology Hematology Care, Inc.
state: Ohio
city: Eugene
country: United States
facility: Hematology & Oncology Associates
state: Oregon
city: Pittsburgh
country: United States
facility: AHN Allegheny General Hospital
state: Pennsylvania
city: Arlington
country: United States
facility: Arlington Cancer Center
state: Texas
city: Austin
country: United States
facility: Texas Oncology - Austin
state: Texas
city: Dallas
country: United States
facility: Texas Oncology
state: Texas
city: Sherman
country: United States
facility: Texas Oncology- Denison
state: Texas
city: Arlington
country: United States
facility: US Oncology Investigational Products Center (IPC)
state: Virginia
city: Blacksburg
country: United States
facility: Oncology and Hematology Associates of Southwest Virginia, Inc
state: Virginia
city: Vancouver
country: United States
facility: Northwest Cancer Specialists, PC
state: Washington
city: Capital
country: Argentina
facility: Investigaciones CORI S.R.L.
city: Cardoba
country: Argentina
facility: Centro Médico Privado Centro de Especialidades Médicas Ambulatorias e Investigación Clínica
city: Ciudad Autanoma Buenos Aires
country: Argentina
facility: Centro Medico Barrio Parque
city: Cordoba
country: Argentina
facility: Sanatorio Allende
city: Rosario
country: Argentina
facility: Sanatorio Britanico de Rosario
city: Rosario
country: Argentina
facility: Sanatorio Parque de Rosario
city: Rosario
country: Argentina
facility: Hospital Provincial del Centenario
city: Rosario
country: Argentina
facility: Instituto Medico de la Fundacion Estudios Clinicos
city: San Miguel de Tucumán
country: Argentina
facility: CAIPO - Centro para la Atención Integral del Paciente Oncológico
city: Viedma
country: Argentina
facility: Clínica Viedma
city: Klagenfurt Am Woerthersee
country: Austria
facility: Klinikum Klagenfurt am Woerthersee
city: Linz
country: Austria
facility: Ordensklinikum Linz GmbH, Elisabethinen
city: Wels
country: Austria
facility: Klinikum Wels-Grieskirchen
city: Wien
country: Austria
facility: Krankenhaus Nord - Klinik Floridsdorf
city: Aalst
country: Belgium
facility: Algemeen Ziekenhuis Sint-Lucas
city: Charleroi
country: Belgium
facility: Grand Hopital de Charleroi asbl (GHdC)
city: Mechelen
country: Belgium
facility: AZ Sint-Maarten
city: Namur
country: Belgium
facility: CHU UCL Namur / Site Sainte Elisabeth
city: Belo Horizonte
country: Brazil
facility: Cenantron Centro Avançado de Tratamento Oncologico Ltda
city: Cachoeiro De Itapemirim
country: Brazil
facility: Hospital Evangelico de Cachoeiro de Itapemirim
city: Caxias Do Sul
country: Brazil
facility: Fundacao Universidade De Caxias Do Sul - FUCS/RS
city: Fortaleza
country: Brazil
facility: Instituto do Câncer do Ceará - ICC
city: Ijui
country: Brazil
facility: Oncosite - Centro de Pesquisa Clinica em Oncologia LTDA
city: Porto Alegre
country: Brazil
facility: Irmandade da Santa Casa de Misericordia de Porto Alegre
city: Porto Alegre
country: Brazil
facility: Hospital de Clínicas de Porto Alegre
city: Porto Alegre
country: Brazil
facility: Hospital São Lucas da PUCRS
city: Santa Cruz Do Sul
country: Brazil
facility: Hospital Ana Nery Santa Cruz do Sul
city: Sao Paolo
country: Brazil
facility: Centro Des Pesquisas Clinicas da Fundacao Doutor Amaral Carvalho
city: Sao Paulo
country: Brazil
facility: Instituto Brasiliero de Controle do Cancer IBCC
city: Greenfield Park
country: Canada
facility: Centre Integre de sante et de services sociaux de la Monteregie Centre
city: Moncton
country: Canada
facility: Moncton Hospital
city: Quebec
country: Canada
facility: CISSS des Laurentides
city: Rimouski
country: Canada
facility: Centre de santé et services sociaux de Rimouski-Neigette
city: Victoria
country: Canada
facility: BC Cancer - Victoria
city: Las Condes
country: Chile
facility: Clinica Alemana de Santiago
city: Providencia
country: Chile
facility: Orlandioncologia
city: Providencia
country: Chile
facility: Oncovida- Santiago
city: Puerto Montt
country: Chile
facility: Clinica Puerto Montt
city: Santiago
country: Chile
facility: Biocinetic
city: Temuco
country: Chile
facility: James Lind Centro de Investigacion del Cancer
city: Vina del Mar
country: Chile
facility: Oncocentro APYS
city: Chengdu
country: China
facility: West China Hospital Sichuan University
city: Chongqing
country: China
facility: Chongqing University Cancer Hospital
city: Deyang
country: China
facility: Deyang People's Hospital
city: Fuzhou
country: China
facility: Fujian Cancer Hospital
city: Guangzhou
country: China
facility: The First Affiliated Hospital of Guangzhou Medical University
city: Guangzhou
country: China
facility: Guangzhou First People's Hospital
city: Guangzhou
country: China
facility: Nanfang Hospital, Southern Medical University
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital
city: Hefei
country: China
facility: Anhui Chest Hospital
city: Jiangxi
country: China
facility: The Second Affiliated Hospital of Nanchang University
city: Jinan
country: China
facility: Shandong Cancer Hospital
city: Nanchang
country: China
facility: Jiangxi Chest Hospital
city: Nanjing
country: China
facility: Nanjing Drum Tower Hospital
city: Nanning
country: China
facility: Guangxi Medical University Cancer Hospital
city: Shanghai
country: China
facility: Shanghai Chest Hospital
city: Shanghai
country: China
facility: Shanghai Pulmonary Hospital
city: Shantou
country: China
facility: Cancer Hospital of Shantou University Medical College
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute & Hospital
city: Wuhan
country: China
facility: Union Hospital Tongji Medical College Huazhong University of Science and Technology
city: Wuhan
country: China
facility: Tongji Hospital Tongji Medical College of Hust
city: Xi'an
country: China
facility: The First Affiliated Hospital of Xian Jiaotong University
city: Xinxiang
country: China
facility: The First Affiliated Hospital of Xinxiang Medical College
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
city: Boulogne-Billancourt
country: France
facility: Ambroise-Pare Hospital, Assistance Publique - Hopitaux de Paris
city: Caen
country: France
facility: CHU de Caen
city: Le Mans
country: France
facility: Clinique Victor Hugo, Centre de Cancerologie de la Sarthe
city: Marseille
country: France
facility: Hopital Nord
city: Montpellier
country: France
facility: Institut de Cancer de Montpellier (ICM) - Val d'Aurelle
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Saint-Herblain
country: France
facility: Institut de cancerologie de l'ouest (ICO)
city: Saint-Mandé
country: France
facility: Hopital d'Instruction des Armees (HIA) Begin
city: Saint-Quentin
country: France
facility: Centre Hospitalier de Saint-Quentin
city: Strasbourg
country: France
facility: Institut de Cancerologie Strasbourg Europe (ICANS)
city: Suresnes
country: France
facility: Hôpital Foch
city: Toulon cedex
country: France
facility: CHI de Toulon la Seyne-sur-Mer Hopital Sainte Musse
city: Bochum
country: Germany
facility: Augusta-Kranken-Anstalt gGmbh Klinik für Hämatologie Onkologie und Palliativmedizin
city: Chemnitz
country: Germany
facility: Klinikum Chemnitz gGmbH
city: Essen
country: Germany
facility: Universitatsklinikum Essen / Westdeutsches Tumorzentrum, Innere Klinik (Tumorforschung)
city: Freiburg
country: Germany
facility: Universitätsklinikum Freiburg, Klinik für Innere Medizin I Hämatologie, Onkologie und Stammzelltransplantation
city: Grosshansdorf
country: Germany
facility: LungenClinic Grosshansdorf
city: Halle
country: Germany
facility: Krankenhaus Martha-Maria Halle Dölau
city: Hamburg
country: Germany
facility: Asklepios Kliniken Hamburg
city: Hamburg
country: Germany
facility: Katholisches Marienkrankenhaus gGmbH
city: Hemer
country: Germany
facility: Lungenklinik Hemer, Zentrum fur Pneumologie and Thoraxchirurgie
city: Karlsruhe
country: Germany
facility: Vincentius-Diakonissen-Kliniken gAG, St. Vincentius-Kliniken, Medizinische Klinik 2
city: Kassel
country: Germany
facility: Klinikum Kassel
city: Köln
country: Germany
facility: Kliniken der Stadt Köln ggmbh, Krankenhaus Koln-Merheim/Lungenklinik
city: Lubeck
country: Germany
facility: Universitatsklinikum Schleswig-Holstein
city: Minden
country: Germany
facility: Johannes Wesling Klinikum Minden
city: Munchen
country: Germany
facility: Munchen Klinik Bogenhausen, Klinik fur Pneumologie und Pneumologische Onkologie
city: Offenbach
country: Germany
facility: Sana Klinikum Offenbach GmbH, Medizinische Klinik IV, Hämatologie und Internistische Onkologie
city: Hong Kong
country: Hong Kong
facility: Queen Elizabeth Hospital
city: Hong Kong
country: Hong Kong
facility: Queen Mary Hospital
city: New Territories
country: Hong Kong
facility: Prince of Wales Hospital
city: Beer Seva
country: Israel
facility: Soroka University Medical Center, Itzchak Rager Blvd.
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
city: Nahariya
country: Israel
facility: Oncology Institute, Galilee Medical Center, Route 89 Nahariya-Cabri
city: Petah Tiqva
country: Israel
facility: Rabin Medical Center
city: Rehovot
country: Israel
facility: Kaplan Medical Center
city: Tel Aviv
country: Israel
facility: Tel-Aviv Sourasky Medical Center
city: Avellino
country: Italy
facility: Azienda Ospedaliera San Giuseppe Moscati
city: Candiolo
country: Italy
facility: IRCCS Fondazoine del Piemonte per l'Oncologia
city: Cremona
country: Italy
facility: Azienda Socio Sanitaria Territoriale di Cremona
city: Genova
country: Italy
facility: Ospedale Policlinico San Martino
city: Milano
country: Italy
facility: Ospedale San Raffaele
city: Modena
country: Italy
facility: Azienda Ospedaliero Universitaria di Modena
city: Naples
country: Italy
facility: AORN Cardarelli
city: Napoli
country: Italy
facility: Azienda Ospedaliera dei Colli
city: Pavia
country: Italy
facility: IRCCS Policlinico S. Matteo, Dipartimento Oncologia Ematologia-Oncologia Medica
city: Pesaro
country: Italy
facility: Azienda Sanitaria Territoriale Pesaro e Urbino (AST)
city: Piacenza
country: Italy
facility: Ospedale Guglielmo da Saliceto AUSL di Piacenza
city: Pordenone
country: Italy
facility: Centro di Riferimento Oncologico
city: Rome
country: Italy
facility: Regina Elena Institute for Cancer Research
city: Treviglio
country: Italy
facility: ASST Bergamo Ovest- ospedale di Treviglio
city: Chiba
country: Japan
facility: National Cancer Center Hospital East
city: Ehime
country: Japan
facility: National Hospital Organization Shikoku Cancer Center
city: Fukuoka
country: Japan
facility: Kyushu University Hospital
city: Fukuoka
country: Japan
facility: Kurume University Hospital
city: Hyogo
country: Japan
facility: National Hospital Organization Himeji Medical Center
city: Hyogo
country: Japan
facility: Hyogo Cancer Center
city: Ishikawa
country: Japan
facility: Kanazawa University Hospital
city: Kanagawa
country: Japan
facility: Kanagawa Cancer Center
city: Miyagi
country: Japan
facility: Sendai Kousei Hospital
city: Niigata
country: Japan
facility: Niigata Cancer Center Hospital
city: Osaka
country: Japan
facility: Osaka Metropolitan University Hospital
city: Osaka
country: Japan
facility: Osaka Medical and Pharmaceutical University Hospital
city: Osaka
country: Japan
facility: Kindai University Hospital
city: Osaka
country: Japan
facility: National Hospital Organization Kinki Chuo Chest Medical Center
city: Saitama
country: Japan
facility: Saitama Medical University
city: Dongjak-Gu
country: Korea, Republic of
facility: SMG - SNU Boramae Medical Center
city: Gangnam-Gu
country: Korea, Republic of
facility: Samsung Medical Center
city: Goyang
country: Korea, Republic of
facility: National Cancer Center
city: Heungdeok-Gu
country: Korea, Republic of
facility: Chungbuk National University Hospital
city: Incheon
country: Korea, Republic of
facility: Inha University Hospital
city: Inchon
country: Korea, Republic of
facility: Gachon University Gil Medical Center
city: Seo-gu
country: Korea, Republic of
facility: Kosin University Gospel Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea, Seoul St. Mary's Hospital
city: Suwon-si
country: Korea, Republic of
facility: Ajou University Hospital
city: Suwon
country: Korea, Republic of
facility: The Catholic University of Korea, Saint Vincent's Hospital
city: Mexico
country: Mexico
facility: Health Pharma Professional Research S.A. de C.V.
city: Mitras Centro
country: Mexico
facility: Hospital Universitario Dr. Jose Eleuterio Gonzalez
city: Oaxaca
country: Mexico
facility: Oaxaca Site Management Organization
city: Oaxaca
country: Mexico
facility: Centro de Investigacion Clinica de Oaxaca
city: Orizaba Centro
country: Mexico
facility: Clinical Medical Research SC.
city: Puebla
country: Mexico
facility: Clinica Integral Internacional de Oncologia S de RL de CV
city: Veracruz
country: Mexico
facility: FAICIC Clínical Research
city: Breda
country: Netherlands
facility: Amphia Ziekenhuis
city: Ede
country: Netherlands
facility: Ziekenhuis Gelderse Vallei
city: Groningen
country: Netherlands
facility: Universitair Medisch Centrum Groningen
city: Harderwijk
country: Netherlands
facility: Ziekenhuis St Jansdal
city: Tilburg
country: Netherlands
facility: TweeSteden Ziekenhuis
city: Amadora
country: Portugal
facility: Hospital Prof. Doutor Fernando Fonseca
city: Lisboa
country: Portugal
facility: Instituto Português de Oncologia de Lisboa Francisco Gentil
city: Lisboa
country: Portugal
facility: Fundacao Champalimaud
city: Lisboa
country: Portugal
facility: Centro Hospitalar Universitário Lisboa Norte - Hospital Pulido Valente
city: Lisbon
country: Portugal
facility: Hospital Beatriz Angelo. Hospital de Loures.
city: Porto
country: Portugal
facility: Centro Hospitalar Universitario Sao Joao, EPE
city: Senhora da Hora
country: Portugal
facility: Unidade Local de Saude de Matosinhos EPE - Hospital Pedro Hispano SA
city: Singapore
country: Singapore
facility: Raffles Hospital
city: Singapore
country: Singapore
facility: Tang Tock Seng Hospital
city: Barcelona
country: Spain
facility: Hospital Clinic de Barcelona
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i de Sant Pau
city: Barcelona
country: Spain
facility: Hospital Universitari Dexeus (USP Institut Universitari Dexeus/Hospital Universitari Quiron Dexeus)
city: Barcelona
country: Spain
facility: Hospital Universitari Vall D'Hebron
city: Barcelona
country: Spain
facility: Hospital Parc Tauli
city: Cordoba
country: Spain
facility: Hospital Universitario Reina Sofia
city: Girona
country: Spain
facility: Hospital Doctor Josep Trueta
city: Jaen
country: Spain
facility: Hospital Universitario de Jaen
city: Las Palmas de G.C.
country: Spain
facility: Hospital Universitario de Canarias
city: Madrid
country: Spain
facility: Hospital Universitario Fundacion Jimenez Diaz
city: Madrid
country: Spain
facility: Clinica Universidad de Navarra
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
city: Majadahonda
country: Spain
facility: Hospital Universitario Puerta de Hierro de Majadahonda
city: Reus
country: Spain
facility: Hospital Sant Joan de Reus
city: Rincon de la Victoria
country: Spain
facility: Hospital Regional Universitario de Malaga
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena
city: Seville
country: Spain
facility: Hospital Universitario Virgen del Rocio
city: Valencia
country: Spain
facility: Instituto Valenciano De Oncologia (IVO)
city: Valencia
country: Spain
facility: Hospital Universitari i Politecnic La Fe
city: Valencia
country: Spain
facility: Hospital Vithas Valencia 9 de Octubre
city: Changhua City
country: Taiwan
facility: Changhua Christian Hospital
city: Kaohsiung City
country: Taiwan
facility: E-DA Hospital
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung-Ho Memorial Hospital
city: Kaohsiung
country: Taiwan
facility: Chang Gung Memorial Hospital Kaohsiung
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital
city: Tainan
country: Taiwan
facility: Chi Mei Hospital, Liouying
city: Taipei City
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
city: Taoyuan City
country: Taiwan
facility: Chang Gung Memorial Hospital Linkou Branch of the Chang Gung Medical Foundation
city: Ankara
country: Turkey
facility: Ankara Bilkent Sehir Hastanesi
city: Ankara
country: Turkey
facility: Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi
city: Edirne
country: Turkey
facility: Trakya University Faculty of Medicine
city: Fatih
country: Turkey
facility: Istanbul University Cerrahpasa Medical Faculty Hospital
city: Istanbul
country: Turkey
facility: Goztepe Prof. Dr. Suleyman Yalcın Sehir Hastanesi
city: Istanbul
country: Turkey
facility: Medipol Mega University Hospital
city: Kaakaekmece
country: Turkey
facility: Acibadem Mehmet Ali Aydinlar Universitesi Atakent Hastanesi
city: Malatya
country: Turkey
facility: Turgut Ozal Medical Faculty
city: Colchester
country: United Kingdom
facility: Colchester General Hospital
city: London
country: United Kingdom
facility: St Bartholomew's Hospital, Barts Health NHS Trust
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust, Department of Medical Oncology
city: Southampton
country: United Kingdom
facility: University Hospital Southampton Nhs Foundation Trust
Study officials:
affiliation: Gilead Sciences
name: Gilead Study Director
role: STUDY_DIRECTOR
References: